Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics

Ekaterina Taneva, Shada Sinclair, Pedro Mm Mesquita, Brian Weinrick, Scott A. Cameron, Natalia V. Cheshenko, Kerry Reagle, Bruce Frank, Sujatha Srinivasan, David Fredricks, Marla J. Keller, Betsy Herold

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tenofovir gel and dapivirine ring provided variable HIV protection in clinical trials, reflecting poor adherence and possibly biological factors. We hypothesized that vaginal microbiota modulates pharmacokinetics and tested the effects of pH, individual bacteria, and vaginal swabs from women on pharmacokinetics and antiviral activity. Tenofovir, but not dapivirine, uptake by human cells was reduced as pH increased. Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis. The inhibition of endocytosis mapped to adenine. Adenine increased from 65.5 μM in broth to 246 μM in Gardnerella, but decreased to 9.5 μM in Atopobium supernatants. This translated into a decrease in anti-HIV activity when Gardnerella supernatants or adenine were added to cultures. Dapivirine was also impacted by microbiota, as drug bound irreversibly to bacteria, resulting in decreased antiviral activity. When drugs were incubated with vaginal swabs, 30.7% ± 5.7% of dapivirine and 63.9% ± 8.8% of tenofovir were recovered in supernatants after centrifugation of the bacterial cell pellet. In contrast, no impact of microbiota on the pharmacokinetics of the prodrugs, tenofovir disoproxil fumarate or tenofovir alafenamide, was observed. Together, these results demonstrate that microbiota may impact pharmacokinetics and contribute to inconsistent efficacy.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number13
DOIs
StatePublished - Jul 12 2018

Fingerprint

Tenofovir
Microbiota
Pharmacokinetics
Gardnerella
Adenine
Pharmaceutical Preparations
Endocytosis
Antiviral Agents
Gardnerella vaginalis
HIV
Bacteria
Prodrugs
Biological Factors
Vagina
Centrifugation
Biological Availability
Gels
Clinical Trials

Keywords

  • AIDS/HIV
  • Drug therapy

Cite this

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. / Taneva, Ekaterina; Sinclair, Shada; Mesquita, Pedro Mm; Weinrick, Brian; Cameron, Scott A.; Cheshenko, Natalia V.; Reagle, Kerry; Frank, Bruce; Srinivasan, Sujatha; Fredricks, David; Keller, Marla J.; Herold, Betsy.

In: JCI insight, Vol. 3, No. 13, 12.07.2018.

Research output: Contribution to journalArticle

Taneva, E, Sinclair, S, Mesquita, PM, Weinrick, B, Cameron, SA, Cheshenko, NV, Reagle, K, Frank, B, Srinivasan, S, Fredricks, D, Keller, MJ & Herold, B 2018, 'Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics', JCI insight, vol. 3, no. 13. https://doi.org/10.1172/jci.insight.99545
Taneva, Ekaterina ; Sinclair, Shada ; Mesquita, Pedro Mm ; Weinrick, Brian ; Cameron, Scott A. ; Cheshenko, Natalia V. ; Reagle, Kerry ; Frank, Bruce ; Srinivasan, Sujatha ; Fredricks, David ; Keller, Marla J. ; Herold, Betsy. / Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. In: JCI insight. 2018 ; Vol. 3, No. 13.
@article{2e817133989d474482a8f2466cf77a5d,
title = "Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics",
abstract = "Tenofovir gel and dapivirine ring provided variable HIV protection in clinical trials, reflecting poor adherence and possibly biological factors. We hypothesized that vaginal microbiota modulates pharmacokinetics and tested the effects of pH, individual bacteria, and vaginal swabs from women on pharmacokinetics and antiviral activity. Tenofovir, but not dapivirine, uptake by human cells was reduced as pH increased. Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis. The inhibition of endocytosis mapped to adenine. Adenine increased from 65.5 μM in broth to 246 μM in Gardnerella, but decreased to 9.5 μM in Atopobium supernatants. This translated into a decrease in anti-HIV activity when Gardnerella supernatants or adenine were added to cultures. Dapivirine was also impacted by microbiota, as drug bound irreversibly to bacteria, resulting in decreased antiviral activity. When drugs were incubated with vaginal swabs, 30.7{\%} ± 5.7{\%} of dapivirine and 63.9{\%} ± 8.8{\%} of tenofovir were recovered in supernatants after centrifugation of the bacterial cell pellet. In contrast, no impact of microbiota on the pharmacokinetics of the prodrugs, tenofovir disoproxil fumarate or tenofovir alafenamide, was observed. Together, these results demonstrate that microbiota may impact pharmacokinetics and contribute to inconsistent efficacy.",
keywords = "AIDS/HIV, Drug therapy",
author = "Ekaterina Taneva and Shada Sinclair and Mesquita, {Pedro Mm} and Brian Weinrick and Cameron, {Scott A.} and Cheshenko, {Natalia V.} and Kerry Reagle and Bruce Frank and Sujatha Srinivasan and David Fredricks and Keller, {Marla J.} and Betsy Herold",
year = "2018",
month = "7",
day = "12",
doi = "10.1172/jci.insight.99545",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "13",

}

TY - JOUR

T1 - Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics

AU - Taneva, Ekaterina

AU - Sinclair, Shada

AU - Mesquita, Pedro Mm

AU - Weinrick, Brian

AU - Cameron, Scott A.

AU - Cheshenko, Natalia V.

AU - Reagle, Kerry

AU - Frank, Bruce

AU - Srinivasan, Sujatha

AU - Fredricks, David

AU - Keller, Marla J.

AU - Herold, Betsy

PY - 2018/7/12

Y1 - 2018/7/12

N2 - Tenofovir gel and dapivirine ring provided variable HIV protection in clinical trials, reflecting poor adherence and possibly biological factors. We hypothesized that vaginal microbiota modulates pharmacokinetics and tested the effects of pH, individual bacteria, and vaginal swabs from women on pharmacokinetics and antiviral activity. Tenofovir, but not dapivirine, uptake by human cells was reduced as pH increased. Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis. The inhibition of endocytosis mapped to adenine. Adenine increased from 65.5 μM in broth to 246 μM in Gardnerella, but decreased to 9.5 μM in Atopobium supernatants. This translated into a decrease in anti-HIV activity when Gardnerella supernatants or adenine were added to cultures. Dapivirine was also impacted by microbiota, as drug bound irreversibly to bacteria, resulting in decreased antiviral activity. When drugs were incubated with vaginal swabs, 30.7% ± 5.7% of dapivirine and 63.9% ± 8.8% of tenofovir were recovered in supernatants after centrifugation of the bacterial cell pellet. In contrast, no impact of microbiota on the pharmacokinetics of the prodrugs, tenofovir disoproxil fumarate or tenofovir alafenamide, was observed. Together, these results demonstrate that microbiota may impact pharmacokinetics and contribute to inconsistent efficacy.

AB - Tenofovir gel and dapivirine ring provided variable HIV protection in clinical trials, reflecting poor adherence and possibly biological factors. We hypothesized that vaginal microbiota modulates pharmacokinetics and tested the effects of pH, individual bacteria, and vaginal swabs from women on pharmacokinetics and antiviral activity. Tenofovir, but not dapivirine, uptake by human cells was reduced as pH increased. Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis. The inhibition of endocytosis mapped to adenine. Adenine increased from 65.5 μM in broth to 246 μM in Gardnerella, but decreased to 9.5 μM in Atopobium supernatants. This translated into a decrease in anti-HIV activity when Gardnerella supernatants or adenine were added to cultures. Dapivirine was also impacted by microbiota, as drug bound irreversibly to bacteria, resulting in decreased antiviral activity. When drugs were incubated with vaginal swabs, 30.7% ± 5.7% of dapivirine and 63.9% ± 8.8% of tenofovir were recovered in supernatants after centrifugation of the bacterial cell pellet. In contrast, no impact of microbiota on the pharmacokinetics of the prodrugs, tenofovir disoproxil fumarate or tenofovir alafenamide, was observed. Together, these results demonstrate that microbiota may impact pharmacokinetics and contribute to inconsistent efficacy.

KW - AIDS/HIV

KW - Drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85056077640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056077640&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.99545

DO - 10.1172/jci.insight.99545

M3 - Article

C2 - 29997295

AN - SCOPUS:85056077640

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 13

ER -